Nature communications · 2020
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Poh Chek Meng, Carissimo Guillaume, Wang Bei, Amrun Siti Naqiah, Lee Cheryl Yi-Pin, Chee Rhonda Sin-Ling, Fong Siew-Wai, Yeo Nicholas Kim-Wah, Lee Wen-Hsin, Torres-Ruesta Anthony, Leo Yee-Sin, Chen Mark I-Cheng, Tan Seow-Yen, Chai Louis Yi Ann, Kalimuddin Shirin, Kheng Shirley Seah Gek, Thien Siew-Yee, Young Barnaby Edward, Lye David C, Hanson Brendon John, Wang Cheng-I, Renia Laurent, Ng Lisa F P
Аннотация
Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.